Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Speaks at Cannapeutas Clinical Perspective Cannabinoid Symposium

SAN DIEGO, Dec. 4, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that subsidiary HempMeds® Mexico will be a Platinum Sponsor at the Cannapeutas Clinical Perspective Cannabinoid Symposium on Dec. 7 at the National Autonomous University of Mexico in Mexico City. Also, Elizalde, who has contributed greatly to Mexico’s inclusion of cannabis into society and science, will be featured as a special guest speaker at this symposium discussing “A New Age of Standardized Applications for Cannabinoids” on December 7 at 7:30 a.m.

The symposium, entitled “El Simposio Cannabanoides: Una Perspectiva Clinica,” will be a private, exclusive event under the direction of key players in the medical and pharmaceutical fields in Mexico, as well as those involved in the implementation, investigation and education of the use of cannabis in the country. This event will provide an invaluable opportunity for these industry leaders to network regarding the future of the legality of cannabis in Mexico.

“We are excited to sponsor this year’s Cannapeutas Clinical Perspective Cannabinoid Symposium,” said Raul Elizalde, President of HempMeds® Latin America. “The information garnered at this event will ultimately aid in formulating sound policy, medical innovation and infrastructure as Mexico transitions to a federal medical cannabis program.”

Since the establishment of HempMeds® Mexico, the company has worked to promote access to cannabidiol (CBD) products by supporting non-profit organizations that help provide quick access and by working with the government to establish an importation process that allows patients to get Real Scientific Hemp Oil-X™ (RSHO-X™) with ease. HempMeds® Mexico was also the first company to receive a COFEPRIS federal government import permit for a cannabis product, RSHO-X™, for a medical indication. Recently, the company was also the first to receive several other import permits for its cannabis products under new federal regulations released last month.

“Our company was the first to have a federally legal CBD product in Mexico and we look forward to sponsoring an event that is slated to make history as well,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Hopefully, we can end the stigma about cannabis through education initiatives while educating people around the world about the plethora of benefits that cannabinoids have to offer.”

About HempMeds® Mexico

HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.


Andrew Hard, Chief Executive Officer

CMW Media

P. 888-829- 0070

[email protected]